1. Introduction to Research Pharmacy Investigational Drug Control and Patient SafetyCUMC RPRobert B. MacArthur, Pharm.D. 2. “ Why does it take so long and cost so much…

Working with FDA: Biological Products and Clinical Development IND Case Studies Karen D. Jones Chief, Project Management Staff Division of Biologic Oncology Products Office…

1. An exposure control plan must be established in writing-Determine exposures-Procedure’s for evaluating exposures-How and when the exposure methods are to beused.-The…

1. NYSE MKT: MSTXNYSE MKT: MSTXCorporate OverviewApril 3, 2013Brian M. Culley, CEO 2. NYSE MKT: MSTXForward-Looking Statements2This presentation includes forward-looking…

Slide 1Drug Advertising & Promotion: A Practical Guide to Compliance Philip KatzOctober 20, 2011 Partner Hogan Lovells US LLP Slide 2 www.hoganlovells.com 22 Agenda Back…

Slide 1Understanding Research: Getting Your Project Ready for the IRB Jill Stoltzfus, Ph.D. Director, Research Institute [email protected] Slide 2 Todays Objectives Present…

Slide 1Human Investigation Committee 2013 Slide 2  Is It Research?  Is It Human Subjects Research?  Is It Human Subjects Research that requires IRB review? Slide…

1.Standard Operating Procedures R E G U L A T O R YA F F A I R S BII INDUSTRY PROGRAME IN PHARMA REGULATORY AFFAIRS2. INDEX 1 Introduction 2 Standard Operating Procedures3…

1. “The Facility’s Perspective” (FDA) Inspections 2. The SpeakerPatrick R. Ayd RN, MBA2 3. The Facility‘s PerspectiveHow to prepare for an FDA Inspection Understanding…

1. Regenerative Medicine: Impact of Convergence on Drug, Device and Biologics Development Annemarie Moseley, PhD, MD Acting CEO, Aggregate Therapeutics, Inc. 2. It’s a…